Pulse Biosciences Files 8-K Report

Ticker: PLSE · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1625101

Pulse Biosciences, Inc. 8-K Filing Summary
FieldDetail
CompanyPulse Biosciences, Inc. (PLSE)
Form Type8-K
Filed DateJan 14, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-statements, regulation-fd

Related Tickers: PLSE

TL;DR

Pulse Biosciences filed an 8-K, likely with financial updates. Keep an eye out for details.

AI Summary

On January 14, 2025, Pulse Biosciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and a Regulation FD disclosure. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Pulse Biosciences is providing updated information to the SEC, which could include important financial or operational disclosures for investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, with no immediate indication of significant negative events.

Key Players & Entities

  • PULSE BIOSCIENCES, INC. (company) — Registrant
  • 0001625101 (company) — Central Index Key
  • 3841 (company) — Standard Industrial Classification
  • 465696597 (company) — IRS Number
  • DE (company) — State of Incorporation
  • 1231 (company) — Fiscal Year End
  • 001-37744 (company) — SEC File Number
  • 25527869 (company) — Film Number
  • 3957 POINT EDEN WAY (company) — Business Address Street 1
  • HAYWARD (company) — Business Address City

FAQ

What is the primary purpose of this 8-K filing by Pulse Biosciences, Inc.?

The filing is a Current Report on Form 8-K, reporting information as of January 14, 2025, and includes items related to Regulation FD Disclosure and Financial Statements and Exhibits.

What is the exact name of the company filing this report?

The exact name of the registrant is PULSE BIOSCIENCES, INC.

In which state was Pulse Biosciences, Inc. incorporated?

Pulse Biosciences, Inc. was incorporated in Delaware.

What is the principal executive office address for Pulse Biosciences, Inc.?

The principal executive offices are located at 601 Brickell Key Drive, Suite 1080, Miami, Florida 33131.

What is the telephone number for Pulse Biosciences, Inc.?

The registrant's telephone number, including area code, is 510-906-4600.

Filing Stats: 719 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2025-01-14 08:59:46

Key Financial Figures

  • $0.001 — ange on Which Registered Common stock, $0.001 par value per share PLSE The Nasdaq

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 14, 2025, Pulse Biosciences, Inc., a Delaware corporation (the "Company"), posted an updated investor presentation on its website. The updated investor presentation (the "Investor Deck") discloses recent progress in the Company's ongoing product development programs relating to its proprietary CellFX nsPFA 360 Cardiac Catheter, its CellFX nsPFA Cardiac Clamp, and its CellFX nsPFA Percutaneous Electrode. The Company expects to use this updated investor presentation, either in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. A copy of the Investor Deck is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. The Investor Deck is also available on the Company's website at www.pulsebiosciences.com under "Investors." Except for the Investor Deck, information contained on, or accessible through, the Company's website is not a part of, and is not incorporated by reference in, this Current Report on Form 8-K. The information contained in the Investor Deck itself is summary information only and it contains forward looking statements that are subject to risks and uncertainties, including those set forth in the Company's filings with the U.S. Securities and Exchange Commission. Also, the information in the Investor Deck is as of January 2025, and the Company undertakes no obligation to publicly update or revise the information contained in the Investor Deck or this Item 7.01, except as required by law, although it made do so from time to time. The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed " filed " for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act " ), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securiti

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Investor Deck, dated January 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: January 14, 2025 By: /s/ Paul A. LaViolette Paul A. LaViolette Chief Executive Officer (Principal Executive and Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.